Amgen’s Xgeva Wins U.K. NICE Backing for Some Cancer Patients

Amgen Inc. (AMGN)’s Xgeva won the backing of the U.K.’s health-cost agency as a treatment for some patients whose cancer has spread to their bones.

The drug, also called denosumab, is an option for breast- cancer patients with bone metastases, though not for men with prostate cancer that has spread, the National Institute for Health and Clinical Excellence said today in a statement on its draft recommendations. Xgeva may also be a cost-effective treatment for patients with solid tumors other than breast or prostate cancers if zoledronic acid or disodium pamidronate would otherwise be prescribed for these patients, according to the agency, known as NICE.

The drug should only be prescribed if Amgen, based in Thousand Oaks, California, provides it at a discounted rate, NICE said, adding that the discount was confidential.

To contact the reporter on this story: Kristen Hallam in London at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.